Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis

2021 ◽  
Author(s):  
Julio Ramírez ◽  
José Inciarte-Mundo ◽  
Andrea Cuervo ◽  
Raquel Celis ◽  
Virginia Ruiz-Esquide ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Established Rheumatoid Arthritis ◽  
Long Term Outcomes ◽  
Remission Criteria

Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study

2017 ◽  
Vol 37 (6) ◽  
pp. 993-997 ◽  
Author(s):  
Nicole Pamplona Bueno de Andrade ◽  
Rafael Mendonça da Silva Chakr ◽  
Ricardo Machado Xavier ◽  
Daniela Viecceli ◽  
Ricardo Henrique Bilycz Correa ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Daily Practice ◽  
Treat To Target ◽  
Established Rheumatoid Arthritis ◽  
Long Term Outcomes ◽  
Target Strategy

Long-Term Outcomes in Rheumatoid Arthritis

Rheumatology ◽  
1995 ◽  
Vol XXXIV (suppl 4) ◽  
pp. 59-73 ◽  
Author(s):  
T. Pincus
Keyword(s):  
Rheumatoid Arthritis ◽  
Long Term Outcomes

scholarly journals Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies

2014 ◽  
Vol 25 (1) ◽  
pp. 11-20 ◽  
Author(s):  
Tsutomu Takeuchi ◽  
Kazuhiko Yamamoto ◽  
Hisashi Yamanaka ◽  
Naoki Ishiguro ◽  
Yoshiya Tanaka ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Certolizumab Pegol ◽  
Early Response ◽  
Long Term Outcomes ◽  
Japanese Studies

scholarly journals The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis

2021 ◽  
Vol 22 (22) ◽  
pp. 12386
Author(s):  
Ludovico De Stefano ◽  
Bernardo D’Onofrio ◽  
Antonio Manzo ◽  
Carlomaurizio Montecucco ◽  
Serena Bugatti
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Presentation ◽  
Adaptive Immune System ◽  
Response To Treatment ◽  
Targeted Intervention ◽  
Long Term Outcomes ◽  
Inflammatory Cascade ◽  
Adaptive Immune ◽  
Disease Subtypes

Differences in clinical presentation, response to treatment, and long-term outcomes between autoantibody-positive and -negative rheumatoid arthritis (RA) highlight the need for a better comprehension of the immunopathogenic events underlying the two disease subtypes. Whilst the drivers and perpetuators of autoimmunity in autoantibody-positive RA have started to be disclosed, autoantibody-negative RA remains puzzling, also due its wide phenotypic heterogeneity and its possible misdiagnosis. Genetic susceptibility appears to mostly rely on class I HLA genes and a number of yet unidentified non-HLA loci. On the background of such variable genetic predisposition, multiple exogeneous, endogenous, and stochastic factors, some of which are not shared with autoantibody-positive RA, contribute to the onset of the inflammatory cascade. In a proportion of the patients, the immunopathology of synovitis, at least in the initial stages, appears largely myeloid driven, with abundant production of proinflammatory cytokines and only minor involvement of cells of the adaptive immune system. Better understanding of the complexity of autoantibody-negative RA is still needed in order to open new avenues for targeted intervention and improve clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document